New drug trial aims to halt dangerous heart scarring
NCT ID NCT07294495
Summary
This study is testing if a drug called Henagliflozin can reduce harmful scarring (fibrosis) in the heart muscle of people with a condition called non-obstructive hypertrophic cardiomyopathy (nHCM). About 150 adult patients will take either the drug or a placebo pill daily for six months. Researchers will use special heart scans to measure changes in the amount of active scarring before and after treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCM - HYPERTROPHIC CARDIOMYOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai East Hospital
Shanghai, Shanghai Municipality, 200120, China
Conditions
Explore the condition pages connected to this study.